Women on GLP-1 receptor agonists lose an average of 1.04 kg more than men on the same drugs. That finding comes from a systematic review of 14 randomized controlled trials covering five different medications, including retatrutide. The gap widens as total weight loss increases. (Yang et al., Journal of Diabetes, March 2025. PMC11880690)
On its own, one extra kilogram is modest. But the researchers found something more interesting in the subgroup analysis: when the drugs were prescribed specifically for obesity rather than diabetes, the sex difference jumped to 4.21 kg. That is not a rounding error. It suggests that the more weight a drug helps someone lose, the more women pull ahead of men.
Why the gap exists
The study does not offer a definitive biological explanation. Hormonal differences in appetite regulation, body composition, and fat distribution are the leading candidates. Women typically carry a higher percentage of body fat than men at the same BMI, which may give GLP-1 drugs more tissue to act on.
There is also a behavioral component that is harder to measure. GLP-1 drugs suppress appetite through central nervous system pathways, and some researchers have suggested these pathways may respond differently based on sex hormones. Estrogen and progesterone both interact with GLP-1 signaling in animal models, though human data on this specific mechanism remains thin.
The Jastreboff Phase 2 retatrutide trial, published in the New England Journal of Medicine in 2023, was deliberately designed with roughly equal numbers of men and women after earlier GLP-1 trials showed this sex-based difference. (Jastreboff et al., NEJM, 2023. PMID: 37366315)
What TRIUMPH-4 adds to the picture
Eli Lilly's first successful Phase 3 trial for retatrutide reported headline numbers in December 2025. Participants on the 12 mg dose lost an average of 28.7% of their body weight at 68 weeks. That translates to roughly 71 pounds from an average starting weight of 249 lbs. (Eli Lilly, TRIUMPH-4 Press Release, December 11, 2025)
TRIUMPH-4 enrolled adults with obesity and knee osteoarthritis. Lilly has not yet published a sex-stratified breakdown of the weight loss data. But given the meta-analysis findings and the trial's mixed-gender enrollment, there is strong reason to expect women in the trial outperformed men on the scale.
Seven more Phase 3 trials are expected to report results throughout 2026. If Lilly publishes subgroup analyses by sex, the picture will get much clearer.
Reddit users are filling in the gaps
Clinical trials take years to publish granular data. In the meantime, female retatrutide users are posting detailed progress reports on Reddit. A recent post on r/Retatrutide from a 37-year-old woman documented her switch from Wegovy to compounded retatrutide, complete with InBody scan data and side-by-side comparisons.
Her experience mirrors a pattern across these communities. Women frequently report faster initial weight loss, stronger appetite suppression, and more noticeable body composition changes than men posting in the same forums. The top post on r/Peptides this week is a retatrutide transformation from 285 lbs to 208 lbs, with 69 upvotes and dozens of comments asking about the protocol.
Anecdotal reports are not clinical evidence. Sample sizes are tiny, reporting is selective, and people who get dramatic results are more likely to post about them. But when anecdotes and meta-analyses point in the same direction, the signal gets harder to ignore.
Dosing considerations for women
Retatrutide is not yet FDA-approved, so there are no official dosing guidelines for anyone. The Phase 2 trial tested doses from 1 mg to 12 mg weekly. Most online communities have converged on a slow titration approach: starting at 1-2 mg and increasing by 1-2 mg every four weeks.
Women in online forums frequently report tolerating lower doses than men for comparable results. Some have settled at 4-6 mg weekly and describe strong appetite suppression and steady weight loss at doses where male users often push higher. Whether this reflects the sex difference seen in the clinical data or just individual variation is impossible to say without controlled studies.
Gastrointestinal side effects remain the primary concern at all doses. Nausea, reduced appetite, and occasional vomiting are the most commonly reported issues. The Phase 2 trial found these were dose-dependent and partially reduced by starting at 2 mg instead of 4 mg.
How retatrutide compares to Wegovy for women
Semaglutide (Wegovy) at 2.4 mg weekly produces average weight loss of about 15-17% over 68 weeks. Retatrutide at 12 mg hit 28.7% in TRIUMPH-4. That is a substantial gap, though the patient populations and trial designs differ enough that a direct comparison requires caution.
The meta-analysis found that semaglutide showed a statistically significant sex difference in weight reduction (1.04 kg favoring women), while dulaglutide showed a similar gap (0.88 kg). The retatrutide-specific sex data from the Phase 2 trial has not been published as a standalone subgroup analysis, but the trial design intentionally accounted for the expected difference.
For women considering a switch from semaglutide to retatrutide, the clinical data supports the idea that retatrutide produces more total weight loss. Whether the female advantage carries over proportionally is an open question that the ongoing Phase 3 program should answer.
What to watch for next
Lilly's seven remaining TRIUMPH trials will report throughout 2026. The data most relevant to women will be any sex-stratified subgroup analyses, particularly from trials focused purely on obesity without comorbidities. If the 4.21 kg female advantage seen in the meta-analysis scales with retatrutide's larger overall weight loss, the gap could be clinically meaningful.
Until then, the available evidence points in a consistent direction. Women appear to lose more weight on GLP-1 drugs than men, the effect grows with stronger drugs, and retatrutide is the strongest in the class. For female users tracking their results, the early data and community reports suggest they may be getting more from the drug than average trial numbers reflect.
For more on retatrutide protocols and research, see our retatrutide guide. For comparisons with other GLP-1 options, read our breakdown of tirzepatide vs semaglutide.
Medical Disclaimer: This article is for informational purposes only and does not constitute medical advice. Consult a licensed healthcare provider before starting any peptide protocol.